2026年第15届世界药学、生物制药及制药技术大会

◆ 会议时间：2026年3月23-26日
◆ 会议地点：捷克共和国布拉格

◆ 会议简介：

世界药学、生物制药学及制药技术大会(PBP)是在行业内有着重要影响力的国际性会议之一，由APGI、APV、ADRITELF联合主办，有超过1300名来自世界各地的科学家和相关人士代表参会，同时有近1000篇论文摘要提交，每两年举办一次，于偶数年的三月或四月举办。

16th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

Dates: 23 – 26 March 2026
Venue: Prague, Czech Republic

以下为上届会议信息

征文投稿：

Online submission

Abstracts can only be submitted online, starting from 01 September 2023. Please use the following URL:
www.worldmeeting.org/home/abstract-submission/

Please use only the prepared doc. documents for your submission of abstracts on Template for papers.

Deadline for short paper submission: 15 November 2023

Abstract registration number/ticket

You receive at the end of a successful submission a registration ticket number. Please annotate this number. With the number you can update your abstract or details and you need the registration ticket number during your registration to the conference. If you have submitted more than one poster you have to endorse all registration ticket numbers during your registration. The registration of the numbers is necessary for the organisational process.

Edit your Abstract

Authors can edit their data and upload the latest version of their abstract by using the function “Status of your abstract” until 28 February 2024. There they can view the current status of acceptance of their abstract as well.

Abstracts

Submitted abstracts will be presented from 19- 21 March 2024, either orally or in poster form. Abstracts will be published on an digital abstract book and listed in the printed conference book with title and authors.

Acceptance of abstracts

Authors will be notified of acceptance of their abstract and the type of presentation (oral or poster) by end of December 2023.

Authors also have the possibility to view the status of their abstract by using the function “Status of your abstract”. There they can view the status as well as they can edit their data and upload the latest version of their abstract.

Status of abstracts

printed – the abstract is corresponding to the specification/the form is accepted for abstract evaluation. The abstract was printed and prepared by organizer for abstract evaluation via the programme committee.
inprocess – the abstract is NOT corresponding to the specification/the form is NOT accepted for abstract evaluation. The author has to adjust the abstract according to the given word template. Once the abstract is changed according to specifiations it will be set to printed.
poster – the abstract is accepted for poster presentation. More information will be provided – the day of presentation immediatley and until the latest one week before the conference starts the panel number.
oral – the abstract is accepted for a short talk. More information will be provided immediately – day, session, time slot and room of presentation.

Oral presentations

There will be 72 slots for oral presentations. The time limit for oral contributions will be exactly 20 minutes including 5 minutes discussion.

Posters

Posters will be presented during special sessions on one specific day. The panels for the poster presentations have the following size: height 120 cm, width 90 cm (DinA0 portrait). The posters must not exceed this size. We suggest to print the posters on paper with a weigh of about 125 to 170 g/m², so that they can be fixed easily without plunge to the ground because it is to heavy or made of (woven) fabric.

Welcome to the 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow, Granada, Rotterdam and due to the COVID crisis in 2021 in a virtual format, the 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology will be held in Vienna, Austria in 2024.

This conference has gained an ever increasing impact among the pharmaceutical scientists: With more than 1000 submitted abstracts and more than 1300 participants (before COVID crisis) it has become a well-established major meeting attracting scientists from all over the world. It is organized every two years, in March or April of the even years.

The entire spectrum of topics ranging from engineering aspects of the manufacturing process, the portfolio of commercially available excipients enabling formulation of a large variety of medicinal products, the underlying physico-chemical principles, cutting-edge characterization techniques as well as potential pitfalls and hurdles to be overcome during product development, manufacturing and characterisation will be addressed.

The conference will be held on 3.5 days: from Monday (noon) until Thursday (evening). From Tuesday to Thursday, 4 parallel sessions with oral presentations will be held:
2 sessions on industry-related topics, presented by distinguished invited speakers, giving overviews on the current state of the art in the respective fields
2 sessions with short talks selected from submitted abstracts, presenting the latest research findings in the broad field of Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology.

During the entire conference, the accompanying exhibition ResearchPharm® provides a cross-disciplinary platform for pharmaceutical scientists working in all fields of drug development in industry, academia and regulatory bodies. This exhibition is steadily growing and offers the possibility to present and learn about the newest trends and products in the area of pharmaceutical ingredients, developing and processing equipment, analytical technologies, medicinal products, medical devices and contract manufacturing.

In addition, young and experienced scientists from academia and industry will present their latest research achievements in the form of poster presentations, allowing for fruitful scientific exchanges with the authors.
The meeting is intended to bring together people working in fundamental and applied academic research, in the chemical and pharmaceutical industry and the regulatory field, offering the opportunity to initiate fruitful discussions and collaborations.